Superior Survival for Breast-conserving Therapy over Mastectomy in Patients with Breast Cancer: A Population-based SEER Database Analysis Across 30 Years

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Jan 23

PMID 36686746

Authors

Shanbao Ke

Wei Wang

Baiyu Li

Xiao Feng

Danfang Yan

Jianbo Liu

Affiliations

Soon will be listed here.

Abstract

Introduction: It has been believed that breast-conserving therapy (lumpectomy plus adjuvant radiation, Lum + RT) and mastectomy without radiation (Mast + NoRT) have equivalent survival outcomes. However, there is a need to re-evaluate the role of lumpectomy plus adjuvant radiation due to changed breast cancer management over time. This study aimed to conduct a population-based study that compare long-term oncologic survival outcomes after Lum + RT vs Mast + NoRT.

Methods: The Surveillance, Epidemiology and End Results database was used to identify female breast cancer patients with a primary localized breast cancer diagnosis from 1988 to 2018. The standardized incidence/mortality ratio (SIR/SMR) for breast cancer recurrence (BCR) and breast cancer-specific death (BSD) was estimated by the SEER*Stat program. Cumulative incidences of BCR and BSD were assessed using Gray's method. We evaluated the effects of Lum + RT vs. Mast + NoRT on breast cancer recurrence-free survival (BRFS) and breast cancer-specific survival (BCSS). Fine-Gray competing risk model analyses, propensity score-adjusted Kaplan-Meier analyses and Cox proportional hazards model analyses were applied.

Results: A total of 205,788 women were included in the study. Patients who underwent Lum + RT had higher SIR of BCR (4.14 [95% confidence interval, CI: 3.94-4.34] vs. 1.11 [95% CI: 1.07-1.14]) and lower SMR (9.89 [95% CI: 9.71-10.08] vs. 17.07 [95% CI: 16.82-17.33]) than patients who underwent Mast + NoRT. Lum + RT was associated with higher competing risk of BCR (adjusted hazard ratio [HR]: 1.996, 95% CI: 1.925-2.069, p < 0.001) and lower competing risk of BSD when compared to Mast + RT (adjusted HR: 0.584, 95% CI: 0.572-0.597, p < 0.001). Multivariate Cox regression analysis revealed similar results (adjusted HR after PSW for BRFS: 1.792, 95% CI 1.716-1.871, p < 0.001; adjusted HR after PSW for BCSS: 0.706, 95% CI 0.688-0.725, p < 0.001). These findings persisted in the sensitivity and subgroup analyses.

Discussion: The present study further confirmed superior long-term survival with lumpectomy plus adjuvant radiation over mastectomy independent of patient characteristics including age, race, time period, historic subtype, tumor size, historic grade and stage, indicating that this benefit may result from the treatment itself.

Citing Articles

Dose advantage of abdominal deep inspiratory breath-hold (aDIBH) in postoperative adjuvant radiotherapy for left breast cancer.

Lai J, Luo H, Hu S, Zhong F, Chen R, Lin H J Egypt Natl Canc Inst. 2024; 36(1):29.

PMID: 39307905 DOI: 10.1186/s43046-024-00234-2.

Surgical options for patients with early-stage breast cancer and pathogenic germline variants: an oncologist perspectives.

Abdel-Razeq H Front Oncol. 2023; 13:1265197.

PMID: 37781190 PMC: 10539549. DOI: 10.3389/fonc.2023.1265197.

References

van Tienhoven G, Voogd A, Peterse J, Nielsen M, ANDERSEN K, Mignolet F . Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM). EORTC Breast Cancer Cooperative Group and the Danish Breast Cancer Cooperative Group. Eur J Cancer. 1999; 35(1):32-8. DOI: 10.1016/s0959-8049(98)00301-3. View

Freedman R, He Y, Winer E, Keating N . Trends in racial and age disparities in definitive local therapy of early-stage breast cancer. J Clin Oncol. 2008; 27(5):713-9. DOI: 10.1200/JCO.2008.17.9234. View

van Dongen J, Voogd A, Fentiman I, LeGrand C, Sylvester R, Tong D . Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst. 2000; 92(14):1143-50. DOI: 10.1093/jnci/92.14.1143. View

Austin P, Stuart E . The performance of inverse probability of treatment weighting and full matching on the propensity score in the presence of model misspecification when estimating the effect of treatment on survival outcomes. Stat Methods Med Res. 2015; 26(4):1654-1670. PMC: 5564952. DOI: 10.1177/0962280215584401. View

Litiere S, Werutsky G, Fentiman I, Rutgers E, Christiaens M, Van Limbergen E . Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol. 2012; 13(4):412-9. DOI: 10.1016/S1470-2045(12)70042-6. View

Gooley T, Leisenring W, Crowley J, Storer B . Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999; 18(6):695-706. DOI: 10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o. View

Chen K, Liu J, Zhu L, Su F, Song E, Jacobs L . Comparative effectiveness study of breast-conserving surgery and mastectomy in the general population: A NCDB analysis. Oncotarget. 2015; 6(37):40127-40. PMC: 4741884. DOI: 10.18632/oncotarget.5394. View

Fisher S, Gao H, Yasui Y, Dabbs K, Winget M . Survival in stage I-III breast cancer patients by surgical treatment in a publicly funded health care system. Ann Oncol. 2015; 26(6):1161-1169. PMC: 4516043. DOI: 10.1093/annonc/mdv107. View

Lim D, Metcalfe K, Narod S . Bilateral Mastectomy in Women With Unilateral Breast Cancer: A Review. JAMA Surg. 2021; 156(6):569-576. DOI: 10.1001/jamasurg.2020.6664. View

10.

Sisco M, Kyrillos A, Lapin B, Wang C, Yao K . Trends and variation in the use of nipple-sparing mastectomy for breast cancer in the United States. Breast Cancer Res Treat. 2016; 160(1):111-120. DOI: 10.1007/s10549-016-3975-9. View

11.

de Boniface J, Szulkin R, Johansson A . Survival After Breast Conservation vs Mastectomy Adjusted for Comorbidity and Socioeconomic Status: A Swedish National 6-Year Follow-up of 48 986 Women. JAMA Surg. 2021; 156(7):628-637. PMC: 8100916. DOI: 10.1001/jamasurg.2021.1438. View

12.

Vinh-Hung V, Burzykowski T, Van De Steene J, Storme G, Soete G . Post-surgery radiation in early breast cancer: survival analysis of registry data. Radiother Oncol. 2002; 64(3):281-90. DOI: 10.1016/s0167-8140(02)00105-6. View

13.

Agarwal S, Pappas L, Neumayer L, Kokeny K, Agarwal J . Effect of breast conservation therapy vs mastectomy on disease-specific survival for early-stage breast cancer. JAMA Surg. 2014; 149(3):267-74. DOI: 10.1001/jamasurg.2013.3049. View

14.

Kurtz J, Amalric R, BRANDONE H, AYME Y, Spitalier J . Local recurrence after breast-conserving surgery and radiotherapy. Helv Chir Acta. 1989; 55(6):837-42. View

15.

Hartmann-Johnsen O, Karesen R, Schlichting E, Nygard J . Survival is Better After Breast Conserving Therapy than Mastectomy for Early Stage Breast Cancer: A Registry-Based Follow-up Study of Norwegian Women Primary Operated Between 1998 and 2008. Ann Surg Oncol. 2015; 22(12):3836-45. PMC: 4595537. DOI: 10.1245/s10434-015-4441-3. View

16.

Southern D, Faris P, Brant R, Galbraith P, Norris C, Knudtson M . Kaplan-Meier methods yielded misleading results in competing risk scenarios. J Clin Epidemiol. 2006; 59(10):1110-4. DOI: 10.1016/j.jclinepi.2006.07.002. View

17.

De la Cruz Ku G, Karamchandani M, Chambergo-Michilot D, Narvaez-Rojas A, Jonczyk M, Principe-Meneses F . Does Breast-Conserving Surgery with Radiotherapy have a Better Survival than Mastectomy? A Meta-Analysis of More than 1,500,000 Patients. Ann Surg Oncol. 2022; 29(10):6163-6188. DOI: 10.1245/s10434-022-12133-8. View

18.

Corradini S, Krug D, Meattini I, Matuschek C, Bolke E, Francolini G . Preoperative radiotherapy: A paradigm shift in the treatment of breast cancer? A review of literature. Crit Rev Oncol Hematol. 2019; 141:102-111. DOI: 10.1016/j.critrevonc.2019.06.003. View

19.

Saleh R, Nadler M, Desnoyers A, Rodin D, Abdel-Qadir H, Amir E . Influence of Competing Risks on Estimates of Recurrence Risk and Breast Cancer-specific Mortality in Analyses of the Early Breast Cancer Trialists Collaborative Group. Sci Rep. 2020; 10(1):4091. PMC: 7058037. DOI: 10.1038/s41598-020-61093-0. View

20.

Hwang E, Lichtensztajn D, Gomez S, Fowble B, Clarke C . Survival after lumpectomy and mastectomy for early stage invasive breast cancer: the effect of age and hormone receptor status. Cancer. 2013; 119(7):1402-11. PMC: 3604076. DOI: 10.1002/cncr.27795. View